Changes in MMP‑2, MMP‑9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis

Bai,Xuesong; Bai,Guang; Tang,Lidong; Liu,Lin; Li,Yufeng; Jiang,Wei

doi:10.3892/etm.2020.8710

Changes in MMP‑2, MMP‑9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis

Authors:
- Xuesong Bai
- Guang Bai
- Lidong Tang
- Lin Liu
- Yufeng Li
- Wei Jiang
View Affiliations

Affiliations: Department of Gastroenterology, Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China
Published online on: April 30, 2020 https://doi.org/10.3892/etm.2020.8710
Pages: 269-274
Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Changes in matrix metalloproteinase (MMP)-2, MMP-9, inflammation, blood coagulation factors and intestinal mucosal permeability in patients with active ulcerative colitis (UC) were investigated. A total of 50 active UC patients treated in our hospital from January 2016 to December 2018 were selected as the UC group, whereas 50 normal subjects receiving physical examination were selected as the control group. Venous blood was drawn to detect the content of early predictors, C‑reactive protein (CRP), follistatin‑like protein 1 (FSTL1) and D‑dimer in serum. The disease activity index (DAI) score was recorded in both groups, the levels of MMP‑2 and MMP‑9 were determined, and the inflammatory factors interleukin (IL)‑1, IL‑6 and tumor necrosis factor (TNF)‑α were also detected. Moreover, the blood coagulation factors, platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen level were detected, the content of lactulose (L) and mannitol (M) in the urine after oral administration of L and M test liquid was determined via high‑performance liquid chromatography in both groups, and the L/M ratio was calculated. In UC group, the content of CRP, FSTL1 and D‑dimer was significantly higher than that in the control group (P<0.05). The DAI score was significantly higher (P<0.05), the content of MMP‑2 and MMP‑9 was remarkably raised (P<0.05), the platelet count, PT, APTT and fibrinogen level were all obviously increased (P<0.05), and the L/M ratio was notably lower (P<0.05) in the UC group than in the control group. In patients with active UC, MMP‑2, MMP‑9 and inflammatory factors were significantly increased, and there were changes in the blood coagulation factors and intestinal mucosal permeability, which further promote the occurrence and development of UC.

View Figures

View References

1	Mason A, Malik S, McMillan M, McNeilly JD, Bishop J, McGrogan P, Russell RK and Ahmed SF: A prospective longitudinal study of growth and pubertal progress in adolescents with inflammatory bowel disease. Horm Res Paediatr. 83:45–54. 2015.PubMed/NCBI View Article : Google Scholar
2	Sun PL and Zhang S: Correlations of 25-hydroxyvitamin D3 level in patients with ulcerative colitis with inflammation level, immunity and disease activity. Eur Rev Med Pharmacol Sci. 22:5635–5639. 2018.PubMed/NCBI View Article : Google Scholar
3	Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, et al: CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 22:598–605. 2016.PubMed/NCBI View Article : Google Scholar
4	Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK, et al: NOR-SWITCH study group: Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet. 389:2304–2316. 2017.PubMed/NCBI View Article : Google Scholar
5	Baumgart DC and Sandborn WJ: Crohn's disease. Lancet. 380:1590–1605. 2012.PubMed/NCBI View Article : Google Scholar
6	Ordás I, Eckmann L, Talamini M, Baumgart DC and Sandborn WJ: Ulcerative colitis. Lancet. 380:1606–1619. 2012.PubMed/NCBI View Article : Google Scholar
7	Ananthakrishnan AN: Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 12:205–217. 2015.PubMed/NCBI View Article : Google Scholar
8	Mbachi C, Attar B, Oyenubi O, Yuchen W, Efesomwan A, Paintsil I, Madhu M, Ajiboye O, Simons-Linares CR, Trick WE and Kotwal V: Association between cannabis use and complications related to ulcerative colitis inhospitalized patients: A propensity matched retrospective cohortstudy. Medicine (Baltimore). 98(e16551)2019.PubMed/NCBI View Article : Google Scholar
9	Jakubowska K, Pryczynicz A, Iwanowicz P, Niewiński A, Maciorkowska E, Hapanowicz J, Jagodzińska D, Kemona A and Guzińska-Ustymowicz K: Expressions of matrix metalloproteinases (MMP-2, MMP-7, and MMP-9) and their inhibitors (TIMP-1, TIMP-2) in inflammatory bowel diseases. Gastroenterol Res Pract. 2016(2456179)2016.PubMed/NCBI View Article : Google Scholar
10	Khan S, Shukla S, Sinha S, Lakra AD, Bora HK and Meeran SM: Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. Int J Biochem Cell Biol. 58:1–16. 2015.PubMed/NCBI View Article : Google Scholar
11	Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D, Karakosta A, Tzanakis N and Peros G: The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 28B:B1875–B1881. 2008.PubMed/NCBI
12	Jakubowska K, Pryczynicz A, Januszewska J, Sidorkiewicz I, Kemona A, Niewiński A, Lewczuk Ł, Kędra B and Guzińska-Ustymowicz K: Expressions of matrix metalloproteinases 2, 7, and 9 in carcinogenesis of pancreatic ductal adenocarcinoma. Dis Markers. 2016(9895721)2016.PubMed/NCBI View Article : Google Scholar
13	Kreijne JE, van der Giessen J, Verhaar AP, Peppelenbosch MP, de Vries AC, van der Woude CJ and Fuhler GM: Fecal matrix metalloproteinase-9 measurement for optimizing detection of disease activity in inflammatory bowel disease. J Clin Gastroenterol. 53:395–397. 2019.PubMed/NCBI View Article : Google Scholar
14	Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, Saenger Y, Fu Y, Ravindran R, Pulendran B, et al: Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. Cell Rep. 9:1856–1870. 2014.PubMed/NCBI View Article : Google Scholar
15	Wang J, Li Y and Qi Y: Effect of glutamine-enriched nutritional support on intestinal mucosal barrier function, MMP-2, MMP-9 and immune function in patients with advanced gastric cancer during perioperative chemotherapy. Oncol Lett. 14:3606–3610. 2017.PubMed/NCBI View Article : Google Scholar
16	Langers AM, Verspaget HW, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ, Hardwick JC, Hommes DW and Sier CF: MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer. 106:1495–1498. 2012.PubMed/NCBI View Article : Google Scholar
17	Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, Pusateri AE, Vos JA, Guymon CH, Wolf SE, et al: Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma. 67:266–276. 2009.PubMed/NCBI View Article : Google Scholar
18	Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH and Singh S: Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: A systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 3:742–753. 2018.PubMed/NCBI View Article : Google Scholar
19	Abraham C and Cho JH: Inflammatory bowel disease. N Engl J Med. 361:2066–2078. 2009.PubMed/NCBI View Article : Google Scholar
20	Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, et al: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 19 (Suppl A):A5–A36. 2005.PubMed/NCBI View Article : Google Scholar
21	17.Soop M, Nygren J, Thorell A and Ljungqvist O: Stress-induced insulin resistance: Recent developments. Curr Opin Clin Nutr Metab Care. 10:181–186. 2007.PubMed/NCBI View Article : Google Scholar
22	Altshuler AE, Penn AH, Yang JA, Kim GR and Schmid-Schönbein GW: Protease activity increases in plasma, peritoneal fluid, and vital organs after hemorrhagic shock in rats. PLoS One. 7(e32672)2012.PubMed/NCBI View Article : Google Scholar
23	Brohi K, Singh J, Heron M and Coats T: Acute traumatic coagulopathy. J Trauma. 54:1127–1130. 2003.PubMed/NCBI View Article : Google Scholar
24	Lu H, Liu H, Wang J, Shen J, Weng S, Han L, Sun T, Qian L, Wu M, Zhu S, et al: The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution. J Cancer Res Clin Oncol. 141:983–992. 2015.PubMed/NCBI View Article : Google Scholar
25	Gao Q, Meijer MJ, Schlüter UG, van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB and Verspaget HW: Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis. 13:693–702. 2007.PubMed/NCBI View Article : Google Scholar
26	Li WL, Wu CH, Yang J, Tang M, Chen LJ and Zhao SL: Local inflammation alters MMP-2 and MMP-9 gelatinase expression associated with the severity of nifedipine-induced gingival overgrowth: A rat model study. Inflammation. 38:1517–1528. 2015.PubMed/NCBI View Article : Google Scholar